The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...

XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ...

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...

YARDLEY, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced peer ...

Xhance (fluticasone propionate) is a brand-name nasal spray that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance has interactions with some other drugs, such as ...

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...